177 Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial
Journal of Nuclear Medicine · 22.05.2025 · jnumed.125.269913
DOI: 10.2967/jnumed.125.269913 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 22.05.2025. Verfasst von Swayamjeet Satapathy und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Docetaxel, Lutetium, Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
177Lu-prostate-specific membrane antigen-617 (177Lu-PSMA-617) has shown positive survival outcomes in metastatic castration-resistant prostate cancer. However, there are limited data in the hormone-sensitive setting. Here, in the CONSOLIDATE trial (177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer), we intended to evaluate the role of 177Lu-PSMA-617 as consolidation therapy for residual disease after chemohormonal treatment in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
Methods
This was an investigator-initiated randomized, parallel-group, open-label phase 2 trial. Synchronous high-volume mHSPC patients treated with androgen-deprivation therapy plus docetaxel and having residual nonprogressive disease after docetaxel completion (defined as prostate-specific antigen [PSA] > 0.2 ng/mL with PSMA-positive disease on 68Ga-PSMA-11 PET/CT) were randomized in a 1:1 ratio to the experimental arm (177Lu-PSMA-617, 7.4 GBq/cycle × 2, 6 wk apart with protocol-permitted standard of care) or control arm (protocol-permitted standard of care alone). The primary endpoint was the proportion of patients achieving a PSA level of 0.2 ng/mL or less at 6 mo from randomization. Secondary endpoints included objective radiographic response rate, radiographic progression-free survival (PFS), PSA PFS, and toxicities.
Results
The trial was terminated early because of poor accrual after the coronavirus disease pandemic and a change in treatment guidelines for mHSPC. Thirty high-volume mHSPC patients were randomized between January 2021 and June 2024. The primary endpoint was achieved in 9 of 15 (60%; 95% CI, 35%-85%) patients in the experimental arm versus 2 of 15 (13%; 95% CI, 0%-30%) in the control arm (risk ratio, 4.5; 95% CI, 1.2-17.4; P = 0.008). The objective radiographic response rates were 8 of 15 (53%; 95% CI, 28%-78%) and 1 of 15 (7%; 95% CI, 0%-19%) in the experimental and control arms, respectively (P = 0.014). The estimated median radiographic PFS and PSA PFS were 18 mo (95% CI, 9-27 mo) and 15 mo (95% CI, 12-18 mo), respectively, in the experimental arm versus 9 mo (95% CI, 4-14 mo) and 9 mo (95% CI, 1-17 mo), respectively, in the control arm. No grade 3 or 4 toxicity was noted with the addition of 177Lu-PSMA-617 in the experimental arm.
Conclusion
In synchronous high-volume mHSPC patients having residual disease after chemohormonal treatment, 177Lu-PSMA-617 consolidation therapy demonstrated promising efficacy and safety outcomes. Larger phase 3 trials are warranted to definitively establish its survival benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Clinical Haematology and Medical Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
- Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India; sood99@yahoo.com.
- Department of Radiation Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India; and.
Zitieren
APA
Satapathy, S., Das, C. K., Goyal, S., Sood, A., Periasamy, K., Aggarwal, P., Preet, K., Singh, S. K., Mavuduru, R. S., Bora, G. S., Sharma, A. P., Prakash, G., Kumar, R., Singh, H., & Mittal, B. R. (2025). 177 Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial. Journal of Nuclear Medicine, jnumed.125.269913. https://doi.org/10.2967/jnumed.125.269913
Vancouver
Satapathy S, Das CK, Goyal S, Sood A, Periasamy K, Aggarwal P, et al. 177 Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial. Journal of Nuclear Medicine. 2025:jnumed.125.269913. doi:10.2967/jnumed.125.269913
BibTeX
@article{Satapathy2025,
author = {Satapathy, Swayamjeet and Das, Chandan K and Goyal, Shikha and Sood, Ashwani and Periasamy, Kannan and Aggarwal, Piyush and Preet, Komal and Singh, Shrawan K and Mavuduru, Ravimohan S and Bora, Girdhar S and Sharma, Aditya P and Prakash, Gaurav and Kumar, Rajender and Singh, Harmandeep and Mittal, Bhagwant R},
title = {177 Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial},
journal = {Journal of Nuclear Medicine},
year = {2025},
pages = {jnumed.125.269913},
doi = {10.2967/jnumed.125.269913}
}
EUVIMED